Traditional
Powder & capsules
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.05 mg/g (LOD)
Detection limit set by lab of 50ppmAlkaloid Ratio
280 mg / 1 mg
Not detected; Limit of Detection (LOD) stated.
Ratio order:
mitragynine : 7-OH.
Skip to alkaloid ratiosMit Therapy
Back to ratios ↑
Back to ratios ↑
Back to ratios ↑
Back to ratios ↑
Back to ratios ↑
Back to ratios ↑
ALKALOID INFORMATION / MITRAGYNINE : 7-HYDROXYMITRAGYNINE
Mit Therapy
Alkaloid & Potency Information
Mit Therapy products featured here are kratom and mitragynine formulations, not concentrated 7-OH formulations. Any 7-OH present is at trace levels, including amounts that may fall below laboratory detection limits.
Trace amounts. A different kind of product.
7-hydroxymitragynine (7-OH) can occur at very low levels in kratom. Trace presence is different from a product formulated around concentrated 7-OH. The information below discloses these small amounts for transparency; it does not identify 7-OH as an added ingredient or a formulation target.
Enhanced
Powder & capsules
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.05 mg/g (LOD)
Detection limit set by lab of 50ppmAlkaloid Ratio
540 mg / 1 mg
Not detected; Limit of Detection (LOD) stated.
Ratio order:
mitragynine : 7-OH.
ONYX
Powder & capsules
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.05 mg/g (LOD)
Detection limit set by lab of 50ppmAlkaloid Ratio
1000 mg / 1 mg
Not detected; Limit of Detection (LOD) stated.
Ratio order:
mitragynine : 7-OH.
Traditional Shots
15 mL liquid extract
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.07 mg
Reporting basis not specifiedAlkaloid Ratio
1600 mg / 1 mg
Reported amount from the sheet; a concentration in mg/mL is not supplied.
Ratio order:
mitragynine : 7-OH.
Spearmint & Unflavored Shots
15 mL liquid extract
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.05 mg
Reporting basis not specifiedAlkaloid Ratio
3000 mg / 1 mg
Reported amount from the sheet; a concentration in mg/mL is not supplied.
Ratio order:
mitragynine : 7-OH.
150 mg Tablets
790 mg net per tablet
7-OH DISCLOSURE
7-Hydroxymitragynine
(7-OH)
(7-OH)
0.05 mg/g (LOD)
Detection limit set by lab of 50ppmAlkaloid Ratio
3750 mg / 1 mg
Not detected; Limit of Detection (LOD) stated.
Ratio order:
mitragynine : 7-OH.
How to read the cards: ratios list mitragynine first and 7-hydroxymitragynine (7-OH) second. The ratios reproduce the current worksheet’s reference entries; they are normalized proportions, not measured whole-package milligram totals. LOD means Limit of Detection. A non-detect does not mean absolute absence. Use the matching lot’s COA for batch-specific results.
Source details: the Traditional, Enhanced and ONYX reference ratios use target mitragynine amounts of 14, 27 and 50 mg divided by 0.05 mg. Traditional Shots uses the worksheet’s 80 mg target divided by 0.05 mg; its separate reported lab entry is 80.2 mg mitragynine and 0.07 mg 7-OH. Spearmint & Unflavored uses the current 150 mg ratio target divided by 0.05 mg; the formulation section separately lists 155 mg per bottle.
Tablet reference: the card reproduces the worksheet’s entered “3750 Mg” and “1 Mg” values as 3750 mg / 1 mg. Its final ratio cell currently returns #VALUE!. These entered values do not establish whole-package masses. With the corrected 790 mg tablet weight, 0.05 mg/g corresponds to 0.0395 mg per tablet; the calculation 150 ÷ 0.0395 is approximately 3797.47:1. The worksheet entry remains a reference pending reconciliation.
Concentrations: the solid-product LOD shown is the worksheet’s 50 ppm converted to 0.05 mg/g. The liquid entries report milligram amounts without a clear per-gram, per-milliliter, serving or bottle basis; they have not been converted to mg/mL. No dry-weight basis or specific 50 g package is asserted because the source does not establish those details.
01 / PRODUCT SPECIFICATIONS
Traditional
Original plant-material powders and capsules.
Mitragynine1.2–1.7%Formulation specification
Total alkaloids1.3–1.8%Formulation specification
Trace 7-OH specification<50 ppmTrace-level specification; not a measured batch result
| Measurement basis | Mitragynine | Total alkaloids |
|---|---|---|
| Per gram of powder | 12–17 mg | 13–18 mg |
| Per powder serving (2 g) | 24–34 mg | 26–36 mg |
| Per capsule | 7–10 mg | 7.5–10.5 mg |
| Per capsule serving (3 capsules) | 21–30 mg | 22–31 mg |
| Package size | Mitragynine / package (mg) | Total alkaloids / package (mg) | Servings / package |
|---|---|---|---|
| 90ct | 630-900 | 660-930 | 30 |
| 150ct | 1050-1500 | 1100-1550 | 50 |
| 300ct | 2100-3000 | 2200-3100 | 100 |
| 60g | 720-1020 | 780-1080 | 30 |
| 120g | 1440-2040 | 1560-2160 | 60 |
| 250g | 3000-4250 | Not listed* | 125 |
| 1kg Powder | 12000-17000 | 13000-18000 | 500 |
*Total alkaloids for the 250 g package are not listed here. Refer to the matching product label and laboratory report for batch-specific information.
02 / PRODUCT SPECIFICATIONS
Enhanced
Extract-enhanced powder and capsules.
Mitragynine2.7%Formulation specification
Total alkaloids3.8%Formulation specification
Trace 7-OH specification<50 ppmTrace-level specification; not a measured batch result
| Measurement basis | Mitragynine | Total alkaloids |
|---|---|---|
| Per gram of powder | 27 mg | 38 mg |
| Per powder serving (2 g) | 54 mg | 76 mg |
| Per capsule (0.56 g net) | 15.12 mg | 21.28 mg |
| Per capsule serving (3 capsules) | 45.36 mg | 63.84 mg |
| Package size | Mitragynine / package (mg) | Total alkaloids / package (mg) | Servings / package |
|---|---|---|---|
| 10ct | 151.2 | 212.8 | ~3.33 |
| 90ct | 1,360.8 | 1,915.2 | 30 |
| 150ct | 2,268 | 3,192 | 50 |
| 300ct | 4,536 | 6,384 | 100 |
| 14g | 378 | 532 | 7 |
| 120g | 3,240 | 4,560 | 60 |
| 250g | 6,750 | 9,500 | 125 |
| 500g | 13,500 | 19,000 | 250 |
Capsule specification: #00 capsule; 0.56 g net fill; gross target 0.69–0.71 g.
03 / PRODUCT SPECIFICATIONS
ONYX
High-potency powder and capsule formulations.
Mitragynine5.0%Formulation specification
Total alkaloids8–10%Formulation specification
Trace 7-OH specification<50 ppmTrace-level specification; not a measured batch result
| Measurement basis | Mitragynine | Total alkaloids |
|---|---|---|
| Per gram of powder | 50 mg | 80–100 mg |
| Per powder serving (2 g) | 100 mg | 160–200 mg |
| Per capsule | 28 mg | 45–56 mg |
| Per capsule serving (3 capsules) | 84 mg | 135–168 mg |
| Package size | Mitragynine / package (mg) | Total alkaloids / package (mg) | Servings / package |
|---|---|---|---|
| 10ct | 280 | 450-560 | ~3.33 |
| 150ct | 4,200 | 6750-8400 | 50 |
| 120g | 6,000 | 9600-12000 | 60 |
04 / PRODUCT SPECIFICATIONS
Traditional Shots
Liquid extract · 15 mL bottle · three 5 mL servings.
Mitragynine / bottle80 mgFormulation specification
Total alkaloids / bottle140 mgFormulation specification
Trace 7-OH specification<50 ppmTrace-level specification; not a measured batch result
| Measurement basis | Mitragynine | Total alkaloids |
|---|---|---|
| Per serving (5 mL) | 26.6 mg | ≈46.67 mg |
| Per bottle (15 mL) | 80 mg | 140 mg |
05 / PRODUCT SPECIFICATIONS
Spearmint & Unflavored Shots
Liquid extract · 15 mL bottle · three 5 mL servings.
Mitragynine / bottle155 mgFormulation specification
Total alkaloids / bottle230 mgFormulation specification
Trace 7-OH specification<50 ppmTrace-level specification; not a measured batch result
| Measurement basis | Mitragynine | Total alkaloids |
|---|---|---|
| Per serving (5 mL) | ≈51.7 mg | ≈76.6 mg |
| Per bottle (15 mL) | 155 mg | 230 mg |
06 / PRODUCT SPECIFICATIONS
150 mg Tablets
Chewable tablets · 790 mg net weight per tablet.
Mitragynine / tablet150 mgFormulation target
Mitragynine / serving37.5 mg¼ tablet · serving specification
Trace 7-OH specification<50 ppmTrace specification: <0.0395 mg per tablet
| Package | Mitragynine / package | Net product weight | Servings / package |
|---|---|---|---|
| 6 tablets | 900 mg | 4,740 mg | 24 |
| 15 tablets | 2,250 mg | 11,850 mg | 60 |
Ingredient: mitragynine extract. Total-alkaloid content is not listed for this product. The 150 mg mitragynine specification and your corrected 790 mg tablet net weight are used here; the source sheet still lists 800 mg. The card’s 3,750:1 entry is a worksheet reference and does not establish a measured amount of 7-OH per tablet.
UNDERSTANDING YOUR PRODUCT
About this information
This page presents specifications for Mit Therapy kratom and mitragynine products. The trace 7-OH disclosures explain the very small amounts that may be present; these products are not presented as concentrated 7-OH formulations. Potency specifications and reference calculations are not certificates of analysis for individual lots.
- Mitragynine (MIT) is the focus of the potency specifications. 7-hydroxymitragynine (7-OH) is disclosed separately at trace levels. Total alkaloids is a broader measurement and is shown separately in the tables.
- Reading the reference ratios: the cards show reference proportions supplied by the worksheet. They are not whole-package milligram declarations. The inputs and unresolved source differences are explained directly below the cards.
- Units matter: mg means milligrams; g means grams; mL means milliliters; ppm means parts per million. A trace 7-OH amount must be read with its measurement basis, such as per gram, per milliliter, per tablet or per package. A disclosure of trace amounts does not mean a product is a concentrated 7-OH formulation.
- Batch information: use the laboratory report matching the lot number on your package for measured results. “Not detected” means the amount was below that laboratory method’s detection limit. Trace amounts may still be present; this is not a claim of absolute absence.
- Serving and package information: serving sizes are specifications, not directions to increase consumption. Follow the label on your specific product.
